Scientists discover cancer markers may be present early during human development

August 05, 2015

Researchers at the Virginia Bioinformatics Institute have uncovered a link between the genomes of cells originating in the neural crest and development of tumors -- a discovery that could lead to new ways to diagnose and treat cancer.

The new finding, recently published in Oncotarget, resolves why some cancer types share genomic and clinical features.

The discovery may also lead to new ways to diagnose and treat brain cancer, such as gliomas, medulloblastomas, and neuroblastomas; and skin cancer, known as melanoma.

More than 22,000 new cases of brain cancer and more than 73,000 new cases of skin cancer and were expected to arise in Americans in 2015, according to the National Cancer Institute.

To reveal when cancer-causing genomic changes occur , a research group led by Harold "Skip" Garner, a professor in the departments of biological science, computer science, and basic science at Virginia Tech Carilion Medical School, analyzed an often ignored part of the human genome -- repetitive DNA sequences referred to as microsatellites.

Over 1 million microsatellites exist in the human genome, including in neural crest tissues, a thin layer of cells within an embryo that contains genetic instructions to build hundreds of cell types, from neurons to adrenal cells.

When cells migrate from the neural crest, researchers say the instructions may become garbled, causing cancer cells to emerge. Neurological tumors, for example, may arise from glial cells that develop from the crest.

Researchers with the institute's Medical Informatics Systems Division say cancer types can be found or predicted from specific markers within these repetitive sequences, known as cancer-associated microsatellite loci, or CAML.

Long considered "junk DNA" or "dark matter" within the genome because their function was unclear, microsatellites are known for their role in certain diseases such as Fragile X and Huntington's disease.

Garner's group has shown that these regions can be informative about diseases ranging from cancer to autism spectrum disorder.

With more study, researchers believe interrelated hereditary and genetic traits of certain cancers can be traced to their common origin at the neural crest, leading to potentially better therapies and easier tumor identification.

The findings have been licensed to Genomeon, a company co-founded by Garner to develop new ways to assess cancer risk, create diagnostics, and explore potential drug targets to help cancer patients.
More resources are available at Virginia Tech News.

Virginia Tech

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to